<?xml version="1.0" encoding="UTF-8"?>
<ref id="B74-viruses-12-00852">
 <label>74.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kleiman</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Senyuta</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Tryakin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Sauter</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Karseladze</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Tjulandin</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Gurtsevitch</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Mueller-Lantzsch</surname>
    <given-names>N.</given-names>
   </name>
  </person-group>
  <article-title>HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors</article-title>
  <source>Int. J. Cancer</source>
  <year>2004</year>
  <volume>110</volume>
  <fpage>459</fpage>
  <lpage>461</lpage>
  <pub-id pub-id-type="doi">10.1002/ijc.11649</pub-id>
  <pub-id pub-id-type="pmid">15095315</pub-id>
 </element-citation>
</ref>
